telacebec
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2015 (NCT02530710)
Timeline
Indications
Mechanism of action
- Mycobacterium tuberculosisINHIBITOR
Mycobacterium tuberculosis inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1- Mol. weight
- 557.02 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3298910 ↗
Also known as
- 6-chloro-2-ethyl-n-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl) imidazo(1,2-a)pyridine-3-carboxamide
- q203
- q203
- q203
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06481163 | Phase 2 | Jul 9, 2024 | Barwon Health, Global Alliance for TB Drug Development |
| NCT04847583 | Phase 2 | Jul 29, 2021 | Qurient Co., Ltd. |
| NCT03563599 | Phase 2 | Jul 31, 2018 | Qurient Co., Ltd. |
| NCT02858973 | Phase 1 | Aug 1, 2016 | Qurient Co., Ltd. |
| NCT02530710 | Phase 1 | Aug 1, 2015 | Qurient Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qurient Co., Ltd. | For profit | 4 | 4 | 2 | 2015 |
| Barwon Health | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Global Alliance for TB Drug Development | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1